List view / Grid view
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...
4 June 2014 | By Novartis
Novartis announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera (PV). Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy...
4 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that by a letter dated June 2, the United States Food and Drug Administration has informed the Company about the closure of the Warning Letter...
4 June 2014 | By ARIAD Pharmaceuticals Inc
ARIAD Pharmaceuticals, Inc. announced preliminary safety and efficacy data from the discontinued Phase 3 EPIC trial of Iclusig® (ponatinib) vs. imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia...
4 June 2014 | By Daiichi Sankyo
As announced in releases dated April 7 and 11, 2014, Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has entered into agreements with Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) in connection with merger of Ranbaxy Laboratories Limited (“Ranbaxy”) into Sun Pharma. Daiichi Sankyo hereby announces additional information regarding the details of this…
3 June 2014 | By kdc communication
GlaxoSmithKline’s quest for improved anti-malarial treatments has been revolutionized by the speed and reliability of the HP D300 Digital Dispenser...
3 June 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product...
3 June 2014 | By Amgen
Amgen announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma...
3 June 2014 | By AstraZeneca
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors...
3 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced results of the pre-specified individual, as well as the exploratory combined, analyses of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)...
3 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab...
2 June 2014 | By kdm communications
Cresset is pleased to announce that the Centre for Chemical Biology and Therapeutics at The Institute for Stem Cell Biology and Regenerative Medicine (inStem), a state-of-the-art research institute in Bangalore, India...
2 June 2014 | By Roche
Roche announced the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA...
2 June 2014 | By Novartis
Novartis announced the appointment of Bruno Strigini, as President of Novartis Oncology...
2 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival...
